Literature DB >> 29483059

SGLT2 inhibitors and GLP-1 receptor agonists: a sound combination.

Christophe De Block1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29483059     DOI： 10.1016/S2213-8587(18)30031-7

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN： 2213-8587            Impact factor:   32.069


× No keyword cloud information.
  3 in total

1.  Efficacy and Safety Over 2 Years of Exenatide Plus Dapagliflozin in the DURATION-8 Study: A Multicenter, Double-Blind, Phase 3, Randomized Controlled Trial.

Authors:  Serge A Jabbour; Juan P Frías; Azazuddin Ahmed; Elise Hardy; Jasmine Choi; C David Sjöström; Cristian Guja
Journal:  Diabetes Care       Date:  2020-08-18       Impact factor: 19.112

2.  Biochemical Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors by Cardiovascular Risk Profile and Volume Status in a Real-World Diabetic Population.

Authors:  Mauro Gitto; Alexios S Kotinas; Riccardo Terzi; Angelo Oliva; Jorgele Zagoreo; Bernhard Reimers; Giulio G Stefanini; Marco Mirani; Giuseppe Favacchio; Gianluigi Condorelli; Cristina Panico
Journal:  J Cardiovasc Pharmacol       Date:  2022-07-01       Impact factor: 3.271

3.  Switching to Versus Addition of Incretin-Based Drugs Among Patients With Type 2 Diabetes Taking Sodium-Glucose Cotransporter-2 Inhibitors.

Authors:  Kristy T K Lau; Carlos K H Wong; Ivan C H Au; Wallis C Y Lau; Kenneth K C Man; Celine S L Chui; Ian C K Wong
Journal:  J Am Heart Assoc       Date:  2022-03-24       Impact factor: 6.106
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.